Aradigm

Aradigm (Aradigm Health) is a benefits platform for cell and gene therapies (CGTs) structured as a public benefit corporation. It positions itself as a comprehensive CGT "carve-out": it assumes responsibility for paying CGT claims on behalf of self-insured employers and health plans, contracts with a national network of provider "centers of excellence," contracts directly with manufacturers for volume-based discounts and performance guarantees, and provides concierge care coordination for patients navigating treatment.

The company's model is organized around a large-scale pooled risk fund. Purchasers pay a predictable premium into the pool; Aradigm takes on the financial volatility of individual multi-million-dollar claims, pays providers upfront to remove their cash-flow and inventory risk, and monitors patients longitudinally so that payments tied to performance guarantees can be clawed back if therapies do not deliver the promised outcomes. Aradigm cites CGT treatment costs of roughly $1 million to $4 million or more per patient, wide price variation between payers and providers (including CAR-T episode cost variation of over 242 percent between providers with similar outcomes), and an expected sharp increase in approvals over the next three to five years as the drivers of demand for this infrastructure.

The platform was co-designed over roughly six months with a development cohort of 15 large U.S. employers and six payers (three national and three regional). Aradigm launched publicly from stealth on December 9, 2025 and stated it would go live with its first customers in April 2026.

Founding story

Aradigm was founded after a search for an existing market solution to the cost and access problems created by multi-million-dollar cell and gene therapies found only piecemeal approaches; Andreessen Horowitz led a $5 million seed round in 2024 to build the model, which was then co-designed with large employers and payers. It was established as a public benefit corporation.

Business model

Aradigm operates a transparent, cost-plus pass-through model: it charges a small fixed percentage of the risk pool to cover its own expenses, uses the remainder to pay CGT claims and associated care, and returns unspent funds at year end to the contributing employers and payers. Revenue is therefore tied to administering the pool rather than to margin on claims or to denying care. On the supply side, the company negotiates volume-based discounts and performance guarantees with manufacturers and favorable reimbursement rates with a contracted network of centers of excellence.

A small, fixed administrative percentage taken from the pooled premium contributed by employers and payers, with all remaining funds used to pay claims and any surplus returned to contributors.

Traction

The model was built with a development cohort of 15 of the 50 largest U.S. employers and six payers (three national, three regional). Aradigm reported plans to go live with its first customers in April 2026, and one data provider listed the company at approximately 30 employees as of January 2026.

Latest developments

In December 2025 Aradigm exited stealth and announced a $20 million Series A led by Frist Cressey Ventures with Andreessen Horowitz and Morgan Health participating, proceeds to be used for platform development and expanded health system and payer partnerships ahead of an April 2026 customer go-live.